Metrics as of 10/13/2026, 06:36 PM (Berlin time), refresh in progress.
MeiraGTx Holdings Stock
MeiraGTx Holdings plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Alexandria Forbes
- Employees
- 393
- Market cap
- $944 M
- IPO
- 08/06/2018
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry…
MeiraGTx Holdings stock: price history
1D
-2.0%
1W
-4.0%
1M
-20.5%
6M
-9.9%
YTD
+28.0%
1Y
+29.9%
2Y
+139.4%
5Y
-20.4%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~18% stronger price swings than usual
MeiraGTx Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 30/09/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
MeiraGTx Holdings plc is a clinical-stage company specializing in the development of gene therapies for the treatment of severe diseases. The focus is on ophthalmic diseases such as blindness, xerostomia, as well as neurodegenerative conditions including Parkinson's and ALS. Revenues are primarily generated through licensing fees (92.1%) and services related to affiliated entities. A key component of the business model is the company's proprietary Riboswitch system, which is used, among other applications, in a collaboration with Janssen Pharmaceuticals for the development of regulable gene therapies.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about MeiraGTx Holdings
Analyst assessment of MeiraGTx Holdings
PRICE TARGET LOW
US$16.00
CONSENSUS
US$21.00
MEDIAN
US$21.00
PRICE TARGET HIGH
US$26.00
0
STRONG BUY
7
BUY
0
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 14/08/2026
MeiraGTx Holdings stock metrics
P/E
13.41
P/B
4.32
EV/EBITDA
3.48
RETURN ON EQUITY
74.6%
NET MARGIN
50.0%
DEBT/EQUITY
0.52
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
75.7%
FLOAT SHARES
70,136,786
AVG. DAILY VOLUME (30D)
941,226
Insider transactions (SEC)
Naylor Stuart
Forbes Alexandria
Giroux Richard
Naylor Stuart
Naylor Stuart
Institutional holders
Comparable stocks
Frequently asked questions about MeiraGTx Holdings stock
What does MeiraGTx Holdings do?
MeiraGTx Holdings plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Alexandria Forbes, the company employs around 393 people.
The IPO was on 08/06/2018; the stock trades on NASDAQ under the ticker MGTX.
What do analysts say about MeiraGTx Holdings stock?
7 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$21.00, ranging from US$16.00 to US$26.00, with a median of US$21.00.
This is an external assessment, not a statement by Market Jury.
When does MeiraGTx Holdings report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 18% stronger than usual.
Does MeiraGTx Holdings pay a dividend?
No, MeiraGTx Holdings currently does not pay a dividend.
Which stocks are comparable to MeiraGTx Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get MeiraGTx Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess MeiraGTx Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.